1 |
Ghosh A, Greenberg ME. Calcium signaling in neurons: molecular mechanisms and cellular consequences. Science. 1995;268:239-247.
DOI
ScienceOn
|
2 |
Holz RW, Senter RA, Frye RA. Relationship between uptake and catecholamine secretion in primary dissociated cultures of adrenal medulla. J Neurochem. 1982;39:635-646.
DOI
|
3 |
Suzuki M, Muraki K, Imaizumi Y, Watanabe M. Cyclopiazonic acid, an inhibitor of the sarcoplasmic reticulum -pump, reduces -dependent currents in guinea-pig smooth muscle cells. Br J Pharmacol. 1992;107:134-140.
DOI
ScienceOn
|
4 |
Challis RA, Jones JA, Owen PJ, Boarder MR. Changes in inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate mass accumulations in cultured adrenal chromaffin cells in response to bradykinin and histamine. J Neurochem. 1991; 56:1083-1086.
DOI
|
5 |
Dendorfer A, Raasch W, Tempel K, Dominiak P. Interactions between the renin-angiotensin system (RAS) and the sympathetic system. Basic Res Cardiol. 1998;93 Suppl 2:24-29.
DOI
ScienceOn
|
6 |
Stoehr SJ, Smolen JE, Holz RW, Agranoff BW. Inositol trisphosphate mobilizes intracellular calcium in permeabilized adrenal chromaffin cells. J Neurochem. 1986;46:637-640.
DOI
|
7 |
Dunn LA, Holz RW. Catecholamine secretion from digitonintreated adrenal medullary chromaffin cells. J Biol Chem. 1983;258:4989-4993.
|
8 |
Marley PD, McLeod J, Anderson C, Thomson KA. Nerves containing nitric oxide synthase and their possible function in the control of catecholamine secretion in the bovine adrenal medulla. J Auton Nerv Syst. 1995;54:184-194.
DOI
ScienceOn
|
9 |
Oset-Gasque MJ, Parramon M, Hortelano S, Bosca L, Gonzalez MP. Nitric oxide implication in the control of neurosecretion by chromaffin cells. J Neurochem. 1994;63:1693-1700.
|
10 |
Palacios M, Knowles RG, Palmer RM, Moncada S. Nitric oxide from L-arginine stimulates the soluble guanylate cyclase in adrenal glands. Biochem Biophys Res Commun. 1989;165: 802-809.
DOI
ScienceOn
|
11 |
Schwarz PM, Rodriguez-Pascual F, Koesling D, Torres M, Forstermann U. Functional coupling of nitric oxide synthase and soluble guanylyl cyclase in controlling catecholamine secretion from bovine chromaffin cells. Neuroscience. 1998;82: 255-265.
|
12 |
Torres M, Ceballos G, Rubio R. Possible role of nitric oxide in catecholamine secretion by chromaffin cells in the presence and absence of cultured endothelial cells. J Neurochem. 1994;63: 988-996.
|
13 |
Rodriguez-Pascual F, Miras-Portugal MT, Torres M. Effect of cyclic GMP-increasing agents nitric oxide and C-type natriuretic peptide on bovine chromaffin cell function: inhibitory role mediated by cyclic GMP-dependent protein kinase. Mol Pharmacol. 1996;49:1058-1070.
|
14 |
Siragy HM, de Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension. 2000;35:1074-1077.
DOI
ScienceOn
|
15 |
Siragy HM, Carey RM. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension. 1999;33:1237-1242.
DOI
ScienceOn
|
16 |
Gross V, Milia AF, Plehm R, Inagami T, Luft FC. Long-term blood pressure telemetry in AT2 receptor-disrupted mice. J Hypertens. 2000;18:955-961.
DOI
ScienceOn
|
17 |
Pueyo ME, Arnal JF, Rami J, Michel JB. Angiotensin II stimulates the production of NO and peroxynitrite in endothelial cells. Am J Physiol. 1998;274:C214-C220.
DOI
|
18 |
McGehee DS, Role LW. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol. 1995;57:521-546.
DOI
ScienceOn
|
19 |
Boulanger CM, Caputo L, Levy BI. Endothelial AT1-mediated release of nitric oxide decreases angiotensin II contractions in rat carotid artery. Hypertension. 1995;26:752-757.
DOI
ScienceOn
|
20 |
Thorup C, Kornfeld M, Goligorsky MS, Moore LC. AT1 receptor inhibition blunts angiotensin II-stimulated nitric oxide release in renal arteries. J Am Soc Nephrol. 1999;10 Suppl 11:S220- S224.
|
21 |
Takekoshi K, Ishii K, Kawakami Y, Isobe K, Nakai T. Activation of angiotensin II subtype 2 receptor induces catecholamine release in an extracellular -dependent manner through a decrease of cyclic guanosine 3',5'-monophosphate production in cultured porcine adrenal medullary chromaffin Cells. Endocrinology. 2001;142:3075-3086.
DOI
|
22 |
Cheek TR, O'Sullivan AJ, Moreton RB, Berridge MJ, Burgoyne RD. Spatial localization of the stimulus-induced rise in cytosolic in bovine adrenal chromaffin cells. Distinct nicotinic and muscarinic patterns. FEBS Lett. 1989;247:429-434.
DOI
ScienceOn
|
23 |
Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron. 2000;26:13-25.
DOI
ScienceOn
|
24 |
Wada A, Takara H, Izumi F, Kobayashi H, Yanagihara N. Influx of through acetylcholine receptor-associated Na channels: relationship between influx, influx and secretion of catecholamines in cultured bovine adrenal medulla cells. Neuroscience. 1985;15:283-292.
DOI
ScienceOn
|
25 |
Hano T, Mizukoshi M, Baba A, Nakamura N, Nishio I. Angiotensin II subtype 1 receptor modulates epinephrine release from isolated rat adrenal gland. Blood Press Suppl. 1994;5:105-108.
|
26 |
Viveros OH, Wilson SP. The adrenal chromaffin cell as a model to study the co-secretion of enkephalins and catecholamines. J Auton Nerv Syst. 1983;7:41-58.
DOI
ScienceOn
|
27 |
Bader MF, Holz RW, Kumakura K, Vitale N. Exocytosis: the chromaffin cell as a model system. Ann N Y Acad Sci. 2002;971: 178-183.
DOI
ScienceOn
|
28 |
Currie KP. Inhibition of channels and adrenal catecholamine release by G protein coupled receptors. Cell Mol Neurobiol. 2010;30:1201-1208.
DOI
|
29 |
Borges R, Camacho M, Gillis KD. Measuring secretion in chromaffin cells using electrophysiological and electrochemical methods. Acta Physiol (Oxf). 2008;192:173-184.
|
30 |
Livett BG, Marley PD. Noncholinergic control of adrenal catecholamine secretion. J Anat. 1993;183:277-289.
|
31 |
Plunkett LM, Correa FM, Saavedra JM. Quantitative autoradiographic determination of angiotensin-converting enzyme binding in rat pituitary and adrenal glands with 125I-351A, a specific inhibitor. Regul Pept. 1985;12:263-272.
DOI
ScienceOn
|
32 |
Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept. 1993;43:1-20.
DOI
ScienceOn
|
33 |
Israel A, Stromberg C, Tsutsumi K, Garrido MR, Torres M, Saavedra JM. Angiotensin II receptor subtypes and phosphoinositide hydrolysis in rat adrenal medulla. Brain Res Bull. 1995;38:441-446.
DOI
ScienceOn
|
34 |
Wong PC, Hart SD, Zaspel AM, Chiu AT, Ardecky RJ, Smith RD, Timmermans PB. Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2). J Pharmacol Exp Ther. 1990;255:584-592.
|
35 |
Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999;34:724-728.
DOI
|
36 |
Armando I, Carranza A, Nishimura Y, Hoe KL, Barontini M, Terron JA, Falcon-Neri A, Ito T, Juorio AV, Saavedra JM. Peripheral administration of an angiotensin II AT1 receptor antagonist decreases the hypothalamic-pituitary-adrenal response to isolation stress. Endocrinology. 2001;142:3880-3889.
DOI
ScienceOn
|
37 |
Yang G, Xi ZX, Wan Y, Wang H, Bi G. Changes in circulating and tissue angiotensin II during acute and chronic stress. Biol Signals. 1993;2:166-172.
DOI
|
38 |
Mizuno M, Sada T, Ikeda M, Fukuda N, Miyamoto M, Yanagisawa H, Koike H. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol. 1995;285:181-188.
DOI
ScienceOn
|
39 |
Cabassi A, Vinci S, Calzolari M, Bruschi G, Borghetti A. Regional sympathetic activity in pre-hypertensive phase of spontaneously hypertensive rats. Life Sci. 1998;62:1111-1118.
DOI
ScienceOn
|
40 |
Trippodo NC, Frohlich ED. Similarities of genetic (spontaneous) hypertension. Man and rat. Circ Res. 1981;48:309-319.
DOI
ScienceOn
|
41 |
Korner P, Bobik A, Oddie C, Friberg P. Sympathoadrenal system is critical for structural changes in genetic hypertension. Hypertension. 1993;22:243-252.
DOI
ScienceOn
|
42 |
Lee RM, Borkowski KR, Leenen FH, Tsoporis J, Coughlin M. Combined effect of neonatal sympathectomy and adrenal demedullation on blood pressure and vascular changes in spontaneously hypertensive rats. Circ Res. 1991;69:714-721.
DOI
ScienceOn
|
43 |
Borkowski KR, Quinn P. The effect of bilateral adrenal demedullation on vascular reactivity and blood pressure in spontaneously hypertensive rats. Br J Pharmacol. 1983;80: 429-437.
DOI
ScienceOn
|
44 |
Anton AH, Sayre DF. A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines. J Pharmacol Exp Ther. 1962;138:360-375.
|
45 |
Borkowski KR, Quinn P. Adrenaline and the development of spontaneous hypertension in rats. J Auton Pharmacol. 1985;5: 89-100.
DOI
|
46 |
Borkowski KR. Effect of adrenal demedullation and adrenaline on hypertension development and vascular reactivity in young spontaneously hypertensive rats. J Auton Pharmacol. 1991;11: 1-14.
DOI
|
47 |
Wakade AR. Studies on secretion of catecholamines evoked by acetylcholine or transmural stimulation of the rat adrenal gland. J Physiol. 1981;313:463-480.
DOI
|
48 |
Tallarida RJ, Murray RB. Manual of pharmacologic calculations with computer programs. 2nd ed. New York: Springer- Verlag; 1987. p. 132
|
49 |
Hammer R, Giachetti A. Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization. Life Sci. 1982;31:2991-2998.
DOI
ScienceOn
|
50 |
Fulop T, Smith C. Matching native electrical stimulation by graded chemical stimulation in isolated mouse adrenal chromaffin cells. J Neurosci Methods. 2007;166:195-202.
DOI
ScienceOn
|
51 |
Garcia AG, Sala F, Reig JA, Viniegra S, Frias J, Fonteriz R, Gandia L. Dihydropyridine BAY-K-8644 activates chromaffin cell calcium channels. Nature. 1984;309:69-71.
DOI
ScienceOn
|
52 |
Lim DY, Kim CD, Ahn GW. Influence of TMB-8 on secretion of catecholamines from the perfused rat adrenal glands. Arch Pharm Res. 1992;15:115-125
DOI
|
53 |
Goeger DE, Riley RT. Interaction of cyclopiazonic acid with rat skeletal muscle sarcoplasmic reticulum vesicles. Effect on binding and permeability. Biochem Pharmacol. 1989;38: 3995-4003.
DOI
ScienceOn
|
54 |
Shin KH, Kim TE, Kim SE, Lee MG, Song IS, Yoon SH, Cho JY, Jang IJ, Shin SG, Yu KS. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers. J Cardiovasc Pharmacol. 2011;58: 492-499.
DOI
ScienceOn
|
55 |
Seidler NW, Jona I, Vegh M, Martonosi A. Cyclopiazonic acid is a specific inhibitor of the -ATPase of sarcoplasmic reticulum. J Biol Chem. 1989;264:17816-17823.
|
56 |
Redon J, Fabia MJ. Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan. J Renin Angiotensin Aldosterone Syst. 2009;10:147-156.
DOI
|
57 |
Yi S, Kim TE, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. J Cardiovasc Pharmacol. 2011;57:682-689.
DOI
ScienceOn
|
58 |
Lee SE, Kim YJ, Lee HY, Yang HM, Park CG, Kim JJ, Kim SK, Rhee MY, Oh BH; Investigators. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. Clin Ther. 2012;34:552-568.
DOI
ScienceOn
|
59 |
Oparil S, Silfani TN, Walker JF. Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens. 2005;18:287-294.
DOI
ScienceOn
|
60 |
Smith DH. Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade. Am J Hypertens. 2002;15:108S-114S.
DOI
ScienceOn
|
61 |
Teschemacher AG, Seward EP. Bidirectional modulation of exocytosis by angiotensin II involves multiple G-proteinregulated transduction pathways in chromaffin cells. J Neurosci. 2000;20:4776-4785.
|
62 |
Seltzer A, Bregonzio C, Armando I, Baiardi G, Saavedra JM. Oral administration of an AT1 receptor antagonist prevents the central effects of angiotensin II in spontaneously hypertensive rats. Brain Res. 2004;1028:9-18.
DOI
ScienceOn
|
63 |
Uresin Y, Erbas B, Ozek M, Ozkök E, Gürol AO. Losartan may prevent the elevation of plasma glucose, corticosterone and catecholamine levels induced by chronic stress. J Renin Angiotensin Aldosterone Syst. 2004;5:93-96.
DOI
ScienceOn
|
64 |
Noh HJ, Kang YS, Lim DY. Effects of losartan on catecholamine release in the isolated rat adrenal gland. Korean J Physiol Pharmacol. 2009;13:327-335.
DOI
ScienceOn
|
65 |
Lim HJ, Kim SY, Lim DY. Inhibitory effects of olmesartan on catecholamine secretion from the perfused rat adrenal medulla. Korean J Physiol Pharmacol. 2010;14:241-248.
DOI
ScienceOn
|
66 |
Critchley L, Ding B, Fok B, Wang D, Tomlinson B, James A, Thomas GN, Critchley J. The effects of candesartan and ramipril on adrenal catecholamine release in anaesthetized dogs. Eur J Pharmacol. 2004;489:67-75.
DOI
ScienceOn
|
67 |
Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension. 1989;14:177-183.
DOI
|
68 |
Esler M. The sympathetic system and hypertension. Am J Hypertens. 2000;13:99S-105S.
|
69 |
Kim JH, Lee JH, Paik SH, Kim JH, Chi YH. Fimasartan, a novel angiotensin II receptor antagonist. Arch Pharm Res. 2012;35:1123-1126.
DOI
ScienceOn
|
70 |
Miura S, Karnik SS, Saku K. Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst. 2011;12:1-7.
DOI
|
71 |
Bohler S, Pittrow D, Bramlage P, Kirch W. Drug interactions with angiotensin receptor blockers. Expert Opin Drug Saf. 2005;4:7-18.
DOI
ScienceOn
|